Member Info for Ohforthesea

Question in my mind is whether Abingdon are effectively Scale up partners for Innovate Uk…..

I cannot find any evidence of a link. However, both companies were recipients in the 2018 Innovate Uk funding round, at a time when Abingdon were working on mastitis in cows. I see this now from Folium “ we are also developing tests for other bacteria such as Enterococcus, Clostridium and E.coli. And while poultry production is the first step on the ladder, there are numerous applications in animal farming and across the food industry for a test that is quick, simple, and accurate”. I think there may well be a collaboration. But no evidence .

This will be the next stage “ OBD is in the process of obtaining ISO15189 certification for a clinical lab within its Oxford, UK laboratory. Once certified, expected early in 2024, precision medicine tests, like EpiSwitch PSE, will be run there - shortening the overall turnaround time for results.” from September RNS. Wish I had insight on the process or eyes on the ground in Oxford… but I don’t….. so we wait.

Brief words with Sav director but thin piece by Caroline Bailey on 4

Remains a private company. Non traded.

Time will come, and I think soon. For the moment the spotlight is on OBD….

Absolutely right re Vulpes. Newbies should look up Vulpes life sciences and both Stephen and brother Martin Diggle. There is an impressive track record of identifying and developping businesses.

Agreed re finance and both good partnerships and excellent reputation. Was wondering about speed of rollout and any other steps ….this re Cirt “ A unique CPT PLA reimbursement code for the test has been available for use by US payors since October 2022.” wondering about reimbursement Code requirements for this test?

Obviously delighted with the initial price movement but I think there are information gaps that will put some off. A few thoughts….if you look on HL re OBD the last news you see is “losses widen”. I go back though to the May RNS for half year numbers which showed good revenue growth already and the comment “ We continue to focus commercially on growing CiRT sales and establishing the revenue engine while working diligently to launch the PSE clinical test before the end of 2023." So I think updated numbers which we probably wont have for a few months will give a much greater feeling of stability. This is not just a company with a breakthrough discovery that will fold due to finance. Turning to the US, an accredited lab is up and running, unsure if there is a need for a reimbursement code to be in place? Then on to the UK lab and NHS /private usage…. But I think that is for next year. Thoughts around first two areas especially welcome.

Suffice to say that with this one coming good, and Scancell and Proteome not far off Vulpes are shortly going to be rolling in it. Wonder where they go next. Would like to see Chronos Therapeutics go public but prob like recent Oxford spinouts will go to US….

Seriously though re Touchlight do have a look at their website, facilities and experrtise. Brilliant story and an ongoing success. Sadly not available for investment but fascinating.

At Touchlight, we are disrupting the decades-old technology of DNA manufacture to advance genetic medicine. We have developed a novel, synthetic DNA vector, known as doggybone DNA or dbDNA™ and enzymatic manufacturing process, which enables us to produce DNA at unprecedented speed, scale and purity.

For dogbone dna look at the private company Touchlight based at Hampton/sunbury. https://www.touchlight.com/platform-technology/overview/?utm_term=synthetic%20dna%20companies&utm_campaign=Lead+generation&utm_source=adwords&utm_medium=ppc&hsa_acc=4881064295&hsa_cam=14959054942&hsa_grp=128116580523&hsa_ad=553255385934&hsa_src=g&hsa_tgt=kwd-303253519603&hsa_kw=synthetic%20dna%20companies&hsa_mt=b&hsa_net=adwords&hsa_ver=3&gad=1&gclid=CjwKCAjwgZCoBhBnEiwAz35RwrrFlmDCQKvfj9ls0AAgyx5pUD_eRpvVIlHBbd0klofGhWctXWgdghoCc9gQAvD_BwE

Easy there. Enjoy the rns and a coffee……

Wondering about that US commercial office near Astra Zenica offices….

Not 6th but Friday 8th…..my error….runs 5-8. Link still good and they are in impressive company!

Https://world-cdx.com/whats-on/agenda/day-two/

3:00 pm 3D Genomic Liquid Biopsy: Predictive, Prognostic and Diagnostic Biomarkers; from immuno-oncology to early screening of populations at risk

Alexandre Akoulitchev

Chief Scientific Officer, Oxford BioDynamics plc

Synopsis

EpiSwitch® 3D Genomic blood-based platform: from fundamental epigenetic biology to systemic clinical biomarkers for disease diagnosis, prognosis and prediction of treatment response;

EpiSwitch CiRT (Checkpoint Inhibitor Response Test): Highly sensitive clinical blood test for prediction of systemic response to PD-1/-L1 immune checkpoint inhibitors;

EpiSwitch PSE (Prostate Screening Test): novel, highly accurate, multivariant clinical blood test combining PSA with EpiSwitch biomarkers for a breakthrough in prostate cancer screening

Preceding session….astra zenica et al on diagnostics and biomarkers

Nice little mention inside weekend FT money section, top of page 2. No link as I am a paperbased weekend reader. Highlights unique if early stage nature of project. GLA

Likewise expected more….. but no one is looking. Not even the Vulpes followers seem to have noticed the Diggle trades in April…..need a bit of profile raising but I am equally happy to wait for next stage delivery rather than speculaton.

Video

https://www.france24.com/en/tv-shows/focus/20230210-in-portugal-plan-for-lithium-mine-in-rural-village-sparks-controversy